Evaluating the effects of Esmolol on cardiac function in patients with Septic cardiomyopathy by Speck-tracking echocardiography—a randomized controlled trial

• Published in: BMC anesthesiology Vol. 23; no. 1; pp. 51 - 14
• Main Authors: Wang, Junyi, Gao, Xinjing, He, Zhengzhong, Wang, Jinxiang, Xu, Guowu, Li, Tong
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 10.02.2023; BioMed Central; BMC
• Subjects: Analysis; Cardiac arrhythmia; Cardiac function; Cardiac patients; Cardiomyopathies - diagnostic imaging; Cardiomyopathies - drug therapy; Cardiomyopathy; Care and treatment; Catecholamines; Catheters; Clinical trials; Complications and side effects; Echocardiography; Echocardiography - methods; Ejection fraction; Esmolol; Heart; Heart beat; Heart diseases; Heart rate; Hemodynamics; Humans; Infection; Medical prognosis; Mortality; Muscle contraction; Patients; Prospective Studies; Sepsis; Sepsis - complications; Sepsis - drug therapy; Sepsis Induced Cardiomyopathy; Septic Shock; Shock, Septic - drug therapy; Speckle-tracking Echocardiography; Statistical analysis; Stroke Volume; Ultrasonic imaging; Ventricle; Ventricular Function, Left; Sepsis; Septic Shock; Sepsis Induced Cardiomyopathy; Speckle-tracking Echocardiography
• DOI: 10.1186/s12871-023-01983-8
• ISSN: 1471-2253

Esmolol as one treatment of sepsis induced cardiomyopathy (SIC) is still controversial. The objective of this study is to evaluate cardiac function after reducing heart rate by Esmolol in patients with SIC using speck-tracking echocardiography. This study was a single-center, prospective, and randomized controlled study. A total of 100 SIC patients with a heart rate more than 100/min, admitted to the Intensive Care Department of Tianjin Third Central Hospital from March 1, 2020 to September 30, 2021, were selected as the research subjects. They were randomly divided into the Esmolol group (Group E) and the conventional treatment group (Group C), each with 50 cases. The target heart rate of patients in Group E was controlled between 80/min and 100/min. Speck-tracking echocardiography (STE) and pulse indicating continuous cardiac output monitoring (PICCO) were performed in both groups at 1 h, 24 h, 48 h, 72 h, 96 h and 7 d after admission, with data concerning left ventricular global longitudinal strain (GLS), left ventricular ejection fraction (LVEF) and global ejection fraction (GEF), left ventricular systolic force index (dP/dtmx) were obtained, respectively. Hemodynamics and other safety indicators were monitored throughout the whole process. These subjects were followed up to 90 d, with their mortality recorded at Day 28 and Day 90, respectively. Statistical analyses were performed using SPSS version 21. With 24 h of Esmolol, all patients in Group E achieved the target heart rate, and there was no deterioration of GLS, or adverse events. However, compared with those in Group C, their GLS, GEF and dP/dtmx were increased, and the difference was statistically significant (P > 0.05). Compared with patients in Group C, those in Group E had lower short-term mortality, and logistic regression analysis also suggested that Esmolol improved patient outcomes. In SIC patients, the application of Esmolol to lower heart rate decreased their short-term mortality while not making any impairment on the myocardial contractility. Chinese Clinical Trial Registry, ChiCTR2100047513. Registered June 20, 2021- Retrospectively registered, http://www.chictr.org.cn/index.aspx . The study protocol followed the CONSORT guidelines. The study protocol was performed in the relevant guidelines.